DOCSLIB.ORG

Pharmaceuticals Company

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceuticals Company Graduation Project Johnson&johnson DR/ Mohamed Elkaloubi Presented by Dalia Hani Mohamed Ramzy Abdelrahman soliman Sherif Mostafa Mahmoud The company Introduction: Caring for the world, one person at a time... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. Our Family of Companies comprises: The world’s sixth-largest consumer health company The world’s largest and most diverse medical devices and diagnostics company The world’s sixth-largest biologics company And the world’s sixth-largest pharmaceuticals company We have more than 275 operating companies in more than 60 countries employing approximately 128,700 people. Our worldwide headquarters is in New Brunswick, New Jersey, USA. Business highlight 2013 Johnson & Johnson delivered strong results in 2013 led by the outstanding performance in our Pharmaceutical business, the re-launch and strength of key brands in our U.S. over-the- counter (OTC) and other Consumer businesses and continued progress in integrating Synthes, Inc. into our Medical Devices and Diagnostics (MD&D) segment. Results also included advances in our longer-term growth drivers including bringing innovative solutions to the global health care market, executing with excellence, and leading with purpose to advance health and well-being for patients and consumers around the world. PHARMACEUTICAL With $28.1 billion in worldwide sales in 2013, we are the seventh-largest pharmaceuticals business* in the world and the sixth-largest biotech business*. We’re the fastest-growing top 10 Pharmaceutical Company in the United States, Europe and Japan and recorded 15 consecutive quarters of operational sales growth in this segment. Primary contributors to exceptional operational sales growth of 12 percent included REMICADE® (infliximab) and SIMPONI® (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once- monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; PREZISTA® (darunavir), a treatment for HIV; VELCADE® (bortezomib), a treatment for multiple myeloma; and sales of new products. The strong sales results of new products included ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; XARELTO® (rivaroxaban), an oral anticoagulant; the combined sales of COMPLERA®/EVIPLERA® (emtricitabine /rilpivirine/tenofovir disoproxil fumarate) and EDURANT® (rilpivirine) for the treatment of HIV; and INVOKANA® (canagliflozin) for the treatment of adults with Type 2 diabetes. Sales results were negatively impacted by generic competition for ACIPHEX®/ PARIET® (rabeprazole), a proton pump inhibitor for gastrointestinal disorders and CONCERTA® (methylphenidate HCI) for the treatment of attention deficit hyperactivity disorder. During 2013, the company received several regulatory approvals including: U.S. Food and Drug Administration (FDA) approval of OLYSIO™ (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis; FDA approval of IMBRUVICA™ (ibrutinib) capsules for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy; FDA and European Commission (EC) approval of INVOKANA® (canagliflozin), an oral, once-daily, selective sodium glucose co-transporter 2 inhibitor, for the treatment of adults with Type 2 diabetes; FDA approval for the use of STELARA® (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients with active psoriatic arthritis; EC approval of STELARA® (ustekinumab), alone or in combination with methotrexate for active psoriatic arthritis in adults when the response to previous non-biological disease-modifying anti-rheumatic drug therapy has been inadequate; EC approval of an expanded indication for SIMPONI® (golimumab) for the treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6- mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies; FDA approval of SIMPONI® (golimumab) for the treatment of moderately to severely active ulcerative col+itis in adult patients who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine; and FDA approval of SIMPONI® ARIA™ (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate. The EC also approved the use of VELCADE® (bortezomib) as induction therapy in combination with dexamethasone or thalidomide and dexamethasone and applies to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with hematological stem cell transplantation. A Marketing Authorization Application was submitted to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma. Also filed with the EMA, was a once-daily single tablet fixed-dose antiretroviral combination product containing darunavir, a protease inhibitor developed by Janssen-Cilag International NV and marketed as PREZISTA®, with cobicistat, a pharmacokinetic boosting agent, developed by Gilead Sciences, Inc. for use in combination with other HIV medicines. Looking to the future, we are pleased with our focused, deep and productive pharmaceutical pipeline, and expect the growth of our recently launched products to continue. Furthermore, we will continue investing in R&D that’s focused on key unmet needs for patients. As we announced in May at the Pharmaceutical Business Review, we plan to file more than ten new molecular entities (NMEs) for approval between 2013 and 2017, and more than 25 additional line extensions of our in-market products. MEDICAL DEVICES AND DIAGNOSTICS With $28.5 billion in worldwide Medical Devices and Diagnostics (MD&D) sales for 2013, our MD&D segment is the largest medical devices and diagnostics business in the world. Operational sales growth of 6.1 percent included the impact of the acquisition of Synthes, net of the divestiture of the DePuy Trauma business. Excluding this impact, MD&D operational sales growth was 0.1 percent. Primary contributors to operational growth were sales from the acquisition of Synthes and DePuy Synthes Joint Reconstruction products in the Orthopaedics business, Biosense Webster’s electrophysiology products in the Cardiovascular Care business, the Vision Care business, as well as biosurgicals and international sales of energy products in the Specialty Surgery business. Our MD&D business is anchored by 11 “billion-dollar-plus-platforms” including vision care, trauma, sutures, endoscopy, and electrophysiology. The FDA approved EVARREST™ Fibrin Sealant Patch, a novel product that rapidly and reliably aids in stopping bleeding during surgery. In orthopaedics, the ATTUNE® Knee System, developed with innovative proprietary technology, is off to a great start with over 23,000 implants worldwide. The ENSEAL® G2 Articulating Tissue Sealer, the world’s first articulating advanced bipolar product, is making it easier for surgeons around the world to access difficult-to-reach parts of the anatomy. Finally, our THERMOCOOL® SMARTTOUCH® Catheter enhances the safety and efficacy of an ablation procedure by measuring the force of the catheter’s tip inside the heart. These are just a few of the innovations that continue to strengthen our worldwide leadership position in medical devices and diagnostics, where 85 percent of our key platforms hold the number one or number two position in the market. Integrating Synthes has been our priority and we’ve made good progress. DePuy Synthes Companies is the world’s largest and most comprehensive orthopaedics company within a $44 billion market with strong fundamentals, and is primed to offer new, value-added solutions that will help transform health care delivery. In January 2014, we announced receipt of a binding offer from The Carlyle Group to acquire the Ortho-Clinical Diagnostics business for approximately $4 billion. We are in an acceptance period that will end on March 31, 2014 — and expect the transaction will close toward the middle of this year. CONSUMER With $14.7 billion in worldwide sales in 2013, our Consumer segment is the sixth-largest health care consumer business in the world and achieved operational sales growth of 2.8 percent. Our near-term priority is to deliver a reliable supply of OTC products to the U.S. marketplace. Last year, we met our objective of returning approximately 75 percent of our
Load more

Recommended publications
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • Johnson & Johnson
    JOHNSON & JOHNSON FORM 10-K (Annual Report) Filed 02/22/13 for the Period Ending 12/30/12 Address ONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK, NJ 08933 Telephone 732-524-2455 CIK 0000200406 Symbol JNJ SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/12 http://www.edgar-online.com © Copyright 2013, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2012 Commission file number 1-3215 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State of incorporation) (I.R.S. Employer Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Name of each exchange on which registered Common Stock, Par Value $1.00 New York Stock Exchange Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Manufacturers and Wholesalers Street
    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
    [Show full text]
  • Towards the Creation of Polymer Composites Which Can Be
    TOWARDS THE CREATION OF POLYMER COMPOSITES WHICH CAN BE REFILLED WITH ANTIBIOTICS AFTER IMPLANTATION FOR INFECTION TREATMENT By ERIKA LEAH CYPHERT Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Dissertation Advisor: Horst von Recum, Ph.D. Department of Biomedical Engineering CASE WESTERN RESERVE UNIVERSITY January 2021 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Erika Leah Cyphert Candidate for the Doctor of Philosophy degree*. (signed) Steven Eppell, Ph.D. (chair of committee) Horst von Recum, Ph.D. Eben Alsberg, Ph.D. Agata Exner, Ph.D. Jonathan Pokorski, Ph.D. (date) September 25, 2020 *We also certify that written approval has been obtained for any proprietary material contained therein. 2 To my grandparents with love – Phil and Ann Cyphert Ted and Dorothy Lippold Florence Miller 3 TABLE OF CONTENTS TABLE OF CONTENTS………………………………………………………………..4 LIST OF TABLES…………………………………………………………………..….10 LIST OF FIGURES…………………………………………………………………….13 LIST OF ABBREVIATIONS……………………………………………………….…21 ACKNOWLEDGEMENTS……………………………………………………………24 ABSTRACT…………………………………………………………………………..…27 CHAPTER 1: DIAGNOSIS AND BIOMATERIAL-BASED TREATMENTS FOR PERIPROSTHETIC JOINT INFECTIONS………………………………………….29 1.1. LIMITATIONS OF CLINICAL TREATMENT OF PERIPROSTHETIC INFECTION…………………………………………………………………30 1.1.1. INTRODUCTION…………………………………………….…30 1.1.2. ISOLATION OF MICROBIAL ORGANISMS………………....33 1.1.3. POSSIBLE UNDERLYING PATIENT COMORBIDITIES……33 1.1.4. BIOFILM FORMATION AND BACTERIAL RESISTANCE…34 4 1.1.5. REVISION PROCEDURES/INITIAL TREATMENT FAILURES....................................................................................36 1.1.6. SUMMARY……………………………………………………...37 1.2. NOVEL TREATMENT MODALITIES FOR PJIS………………………...38 1.2.1. LIMITATIONS WITH TRADITIONAL ANTIBIOTIC-LADEN PMMA BONE CEMENT……………………………………..…38 1.2.2. COMMERCIALLY AVAILABLE ALTERNATIVE BIOMATERIALS FOR ANTIBIOTIC-LADEN PMMA BONE CEMENT………………………………………………………...40 1.2.3.
    [Show full text]
  • Vers Un Modèle D'entreprise Hybride: L'évolution De La Gestion D'un Contexte De Loyauté Réciproque Vers Un Modèle De Marchés; Étude Du Cas De Johnson & Johnson
    UNIVERSITÉ DU QUÉBEC À MONTRÉAL VERS UN MODÈLE D'ENTREPRISE HYBRIDE: L'ÉVOLUTION DE LA GESTION D'UN CONTEXTE DE LOYAUTÉ RÉCIPROQUE VERS UN MODÈLE DE MARCHÉS; ÉTUDE DU CAS DE JOHNSON & JOHNSON MÉMOIRE PRÉSENTÉ COMME EXIGENCE PARTIELLE DELA MAÎTRISE EN ADMINISTRATION DES AFFAIRES (MBA-RECHERCHE) PAR FRÉDÉRIC TREMBLAY Novembre 2008 UNIVERSITÉ DU QUÉBEC À MONTRÉAL Service des bibliothèques Avertissement La diffusion de ce mémoire se fait dans le respect des droits de son auteur, qui a signé le formulaire Autorisation de reproduire et de diffuser un travail de recherche de cycles supérieurs (SDU-522 - Rév.01-2006). Cette autorisation stipule que «conformément à l'article 11 du Règlement no 8 des études de cycles supérieurs, [l'auteur] concède à l'Université du Québec à Montréal une licence non exclusive d'utilisation et de publication de la totalité ou d'une partie importante de [son] travail de recherche pour des fins pédagogiques et non commerciales. Plus précisément, [l'auteur] autorise l'Université du Québec à Montréal à reproduire, diffuser, prêter, distribuer ou vendre des copies de [son] travail de recherche à des fins non commerciales sur quelque support que ce soit, y compris l'Internet. Cette licence et cette autorisation n'entraînent pas une renonciation de [la] part [de l'auteur] à [ses] droits moraux ni à [ses] droits de propriété intellectuelle. Sauf entente contraire, [l'auteur] conserve la liberté de diffuser et de commercialiser ou non ce travail dont [il] possède un exemplaire.» REMERCIEMENTS La réalisation d'un mémoire de maîtrise est un travail exigeant, mais très formateur. Il pousse au dépassement de soi et à la réalisation de rêves autrefois formulés.
    [Show full text]
  • 137814.Pdf (857.3Kb)
    UNIVERSIDAD PANAMERICANA FACULTAD DE FILOSOFÍA Y CIENCIAS SOCIALES ESCUELA DE PEDAGOGÍA HR Redesing C A S O Q U E P R E S E N T A ALEXIS TANIA CORELLA RAMÍREZ P A R A O B T E N E R E L G R A D O D E : MAESTRA EN CAPITAL HUMANO DIRECTOR DE LA TESIS: Dr. DAVID RENE THIERRY GARCÍA MÉXICO, D.F. 17 DE DICIEMBRE DEL 2012 Universidad Panamericana 2 HR Redesing Índice Introducción ....................................................................................................................................................... 3 Marco Contextual ............................................................................................................................................... 4 Historia de Johnson & Johnson ................................................................................................................... 4 Medical Devices & Diagnostics .................................................................................................................... 5 Global Surgery Group ................................................................................................................................. 5 Global Medical Solutions ............................................................................................................................. 6 Global Orthopaedics Group ......................................................................................................................... 6 Filosofía Institucional – Nuestro Credo .....................................................................................................
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • 2017 Health for Humanity Report Progress in Citizenship & Sustainability 2017 Health for Humanity Report 2
    Executive Summary 2017 Health for Humanity Report Progress in Citizenship & Sustainability 2017 Health for Humanity Report 2 Message from Alex Gorsky It was created with the stroke of for you, our shareholders. It’s our way of a pen in 1886. demonstrating how we work to track and deliver on our commitments. James Wood Johnson, who co-founded the See, for example, how we’re eradicating and company with his brother Edward Mead preventing disease. Johnson, handcrafted one the world’s most trusted logos. James wanted the world to We’ve achieved great milestones as a know just how personally and emotionally company this year in our efforts to make connected the two were to the company’s HIV history with the initiation of the first most important reason for being—improving efficacy study for a preventative vaccine. I’m human health. So, he decided to use the encouraged every time I reflect on how far family signature. we’ve come since the 1980s with HIV, once considered a death sentence. All of us are Johnson & Johnson. humbled to be a part of the efforts to treat Placing their name on the company’s and protect—even, one day, prevent—HIV. products was the ultimate measure of I’m also proud of how we’re reimagining the accountability. It was a way of holding way that care is delivered and expanding themselves responsible for their—and their access for the world’s most vulnerable Alex and Pat Gorsky in Valmiki Basti, one of the oldest communities in New Delhi, India, where they visited the company’s—every action.
    [Show full text]
  • I Project Number
    Project Number: DTZ 1103 An Interactive Qualifying Project Report: Submitted to the Faculty of WORCESTER POLYTECHNIC INSTITUTE in partial fulfillment of the requirements for the Degree of Bachelor of Science By Joshua Nitso _____________________________ Kevin Woods _____________________________ Submitted April 23, 2012 Approved by Professor Dalin Tang, Project Advisor _____________________________________________ I ABSTRACT The history of the stock market and selected companies within the pharmaceutical industry were studied using the Internet and Gordon Library as primary resources. An eight-week simulation was conducted on the stock market using different trading techniques that were analyzed and compared for effectiveness. Using these strategies helped develop a basic understanding of the investing world and the relative success of different investment methods. II TABLE OF CONTENTS ABSTRACT .................................................................................................................................... II TABLE OF CONTENTS .............................................................................................................. III TABLE OF FIGURES ....................................................................................................................V TABLE OF TABLES .................................................................................................................. VII 1. INTRODUCTION .....................................................................................................................
    [Show full text]
  • Proceedings – Small Animals
    22nd Annual Scientific Meeting Ergife Palace Hotel, Rome, Italy Proceedings – Small Animals Edited by: Stephen Baines and Martin Owen July 4–6, 2013 Welcome to Rome, welcome to Italy A Warm Welcome to Rome! Dear ECVS Diplomates, residents and colleagues Rome is the place to see! Rome, one of the most famous and historical cities in the southern part of Europe – one of the most important ancient cultural centres of Europe - offers a variety of architectural, cultural and historical highlights. Rome is easily accessible by train and car and by direct flights from most cities in Europe and the rest of the world. Further, we have the marvellous opportunity to host the scientific part of the congress in the Ergife Palace Hotel where all delegates have the possibility to stay. We were able to negotiate very favourable rates and we hope that delegates as well as exhibitors and sponsors will profit from this exceptional deal. The Ergife Palace Hotel caters for all our needs and wishes. It has modern equipped lecture halls that can host the three parallel small animal and the large animal session, and plenty of small lecture rooms and meeting spaces for side events and discussion groups. There is ample space for a large number of exhibitors and lots of space for the luncheon and coffee breaks The scientific programme will feature state-of-the-art lectures and in-depth seminars, for large and small animal specialists, a short communication section, the Residents’ forum and poster presentations. Invited speakers from all over the world, who are established specialists in their field, will present seminars and state-of-the-art lectures.
    [Show full text]
  • Johnson & Johnson
    Johnson & Johnson Johnson & Johnson is a U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer founded in 1886. Its common stock is a component of the Dow Jones Industrial Average and the company is listed among the Fortune 500. Johnson & Johnson ranked at the top of Harris Interactive's National Corporate Reputation Survey for seven consecutive years up to 2005,[2] was ranked as the world's most respected company by Barron's Magazine in 2008,[3] and was the first corporation awarded the Benjamin Franklin Award for Public Diplomacy by the U.S. State Department in 2005 for its funding of international education programs. However, in recent years the company's reputation has been adversely affected by product recalls, fines for pharmaceutical marketing practices, litigation with a group of shareholders, and other legal issues. Johnson & Johnson is headquartered in New Brunswick, New Jersey with the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in over 57 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $65 billion for the calendar year of 2011.[4] Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses. On December 31, 2012, the Food and Drug Administration approved Sirturo, a Johnson & Johnson tuberculosis drug that is the first new medicine to fight the infection in more than forty years.
    [Show full text]
  • Johnson & Johnson
    TRILLIUM ASSET MANAGEMENT January 19, 2021 Via e-mail at [email protected] Securities and Exchange Commission Office of the Chief Counsel Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Request by Johnson & Johnson to omit Proposal submitted by submitted by Trillium Asset Management (“Trillium”) on behalf of Christopher and Anne Ellinger and co-filers. Ladies and Gentlemen, This is a supplement to Trillium Asset Management LLC’s (acting on behalf Christopher and Anne Ellinger and co-filers (together, the “Proponents”)) January 6 and 10, 2021 letters and in response to Johnson & Johnson’s (“J&J”, “JNJ”, or the “Company”) December 16, 2020 and January 15, 2021 letters regarding a shareholder proposal (the "Proposal) submitted to the Company. The Proposal asks J&J to publish a third-party audit on racial impact and civil rights. 1. Johnson & Johnson has misrepresented the essential element of the Proposal. The Company asserts that “the essential objective of the Proposal is to obtain a report on ways Johnson & Johnson can improve the racial impact of its policies, practices, products and services.” That description entirely ignores the third-party audit request as the center of the Proposal. This failure to accurately and fairly describe the Proposal – effectively an effort to twist the words of the Proposal – is fatal for the Company’s argument. As is abundantly clear in a plain reading of the proposal the request is for: a third-party audit (within a reasonable time, at a reasonable cost, and excluding confidential/proprietary information) to review its corporate policies, practices, products, and services, above and beyond legal and regulatory matters; to assess the racial impact of the company's policies, practices, products and services; and to provide recommendations for improving the company’s racial impact.
    [Show full text]